Free Trial

Medical Stocks To Watch Now - April 15th

Eli Lilly and Company logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Eli Lilly (LLY), Revolution Medicines (RVMD) and UnitedHealth Group (UNH) were flagged by MarketBeat's screener as the medical stocks to watch after posting the highest dollar trading volume among medical-sector names in recent days.
  • Eli Lilly is a major pharma with leading diabetes and obesity drugs and is pursuing a reported $10 billion push into AI and neuroscience; Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors for RAS-addicted cancers; and UnitedHealth is a diversified health-care operator combining UnitedHealthcare insurance with Optum health services and pharmacy businesses.
  • MarketBeat previews top five stocks to own in May.

Eli Lilly and Company, Revolution Medicines, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies involved in healthcare and medicine, including pharmaceuticals, biotechnology, medical devices, diagnostics, hospitals, and other clinical or service providers. Investors buy them to gain exposure to healthcare demand and innovation but must weigh industry-specific risks such as regulatory approvals, clinical trial outcomes, and reimbursement or pricing pressures. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

Revolution Medicines (RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Read Our Latest Research Report on RVMD

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Read Our Latest Research Report on UNH

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines